Table 3 Antioxidant activity of the synthesized analogous
From: Design, synthesis and biological potentials of novel tetrahydroimidazo[1,2-a]pyrimidine derivatives
Comp. | % Inhibition | IC50 µg/ml | |||
|---|---|---|---|---|---|
25 µg/ml | 50 µg/ml | 75 µg/ml | 100 µg/ml | ||
1 | 30.56 | 42.68 | 55.52 | 76.45 | 60.30 |
2 | 37.25 | 51.23 | 67.34 | 89.45 | 46.31 |
3 | 20.62 | 35.93 | 56.24 | 69.85 | 68.90 |
4 | 15.71 | 33.96 | 43.59 | 65.21 | 78.60 |
5 | 21.73 | 37.39 | 58.72 | 73.24 | 65.60 |
6 | 25.65 | 30.95 | 51.34 | 67.28 | 72.70 |
7 | 14.59 | 24.78 | 47.64 | 59.45 | 83.20 |
8 | 26.34 | 37.31 | 55.28 | 72.52 | 65.80 |
9 | 32.62 | 48.28 | 65.21 | 82.16 | 51.83 |
10 | 28.89 | 45.85 | 60.27 | 72.56 | 59.20 |
11 | 26.73 | 47.19 | 63.81 | 79.34 | 56.40 |
12 | 17.62 | 42.95 | 56.57 | 68.28 | 67.80 |
13 | 32.47 | 47.61 | 64.92 | 78.52 | 53.06 |
14 | 19.53 | 41.63 | 61.57 | 74.82 | 63.30 |
15 | 22.68 | 39.91 | 57.74 | 71.73 | 65.40 |
16 | 35.95 | 53.23 | 62.58 | 78.84 | 48.81 |
17 | 24.64 | 43.98 | 61.37 | 74.81 | 60.70 |
18 | 32.94 | 48.92 | 59.38 | 72.49 | 55.90 |
19 | 19.62 | 43.81 | 61.52 | 74.49 | 62.60 |
20 | 21.71 | 34.61 | 56.70 | 75.82 | 66.24 |
21 | 15.25 | 33.41 | 47.43 | 65.51 | 77.00 |
22 | 19.26 | 33.16 | 50.16 | 69.25 | 72.90 |
23 | 23.67 | 47.28 | 65.11 | 78.26 | 57.65 |
24 | 23.68 | 47.28 | 56.14 | 72.61 | 62.60 |
Ascorbic acid | 39.52 | 55.74 | 68.25 | 93.61 | 42.52 |